1115-P: Examining Facilitators and Barriers of CGM and Technology Use among Patients with Type 2 Diabetes Mellitus in Community Health Centers
Introduction and Objective: Continuous glucose monitoring (CGM) improves outcomes but is rarely used in community health centers (CHCs). This study aimed to assess CGM use in CHCs in the context of in-person and remote (e.g., telehealth) delivery. Methods: Participants with T2DM were recruited from two Midwest-based CHC systems that care for underserved communities. CGM users and non-users completed a survey and virtual semi-structured interviews with a trained facilitator. Interviews were recorded and transcribed, and themes were identified among CGM non-users and non-users. Results: Twenty-five participants (18 CGM users, 7 non-users, age 48 +13 yrs) were diverse in racial and gender identity (15 black, 6 white, 4 other, 15 female, 8 male, 1 non-binary, 1 transgender) with primarily public insurance (22 Medicare/Medicaid) and 14 unemployed and/or disabled. They reported using internet and cellphones for health information (88%), had apps on phone (88%), and described varying social needs related to transportation (n=14), food (n=10), and housing (n=3). Most utilized EHR portals (n=17), but fewer (n=12) used telemedicine. For CGM non-users, barriers included insurance coverage and lack of device-specific knowledge. CGM users weighed a variety of factors (e.g., reduced need for fingerstick, pain) before deciding; concerns also stemmed from lack of information or prior experience with CGM. Both users and non-users believed that CGM is helpful for diabetes care. Both groups reported learning about CGM outside the clinic through channels such as social media, including specifically YouTube. Conclusion: Advancements in information sharing and health education, along with understanding of social networks, are needed to improve uptake and utilization of CGM among patients with T2DM at CHCs. Disclosure M.E. Wolter: None. E.L. Lam: None. A.S. Boutsicaris: None. J. Gacki-Smith: None. S.E. DeLacey: None. A. Pack: Consultant; Gilead Sciences, Inc. S. Agarwal: Research Support; Dexcom, Inc. A. Berry: None. M.J. O'Brien: None. A. Wallia: Research Support; UnitedHealth Group. Funding NIH NIDDK (5 P30DK020541-4751) and the Chicago Center for Diabetes Translation Research (P30 DK092949)
Read more